TR 380 Mouse Pathology Tables
INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)
EPINEPHRINE HCL
NTP Experiment-Test: 05095-02 Report: PEIRPT05
Study Type: CHRONIC Date: 09/13/94
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 00:50:55
Facility: Battelle Northwest
Chemical CAS #: 55-31-2
Lock Date: None
Cage Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 05095-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC EPINEPHRINE HCL Date: 09/13/94
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 00:50:55
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 1.5MG/M3 3.0MG/M3
FEMALE FEMALE FEMALE
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 50 50 50
Early Deaths
Dead 11 7 9
Moribund 7 8 7
Survivors
Moribund 1
Terminal Sacrifice 32 35 33
Animals Examined Microscopically 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Intestine Small, Duodenum (50) (14) (50)
Adenocarcinoma 1 (2%)
Intestine Small, Jejunum (49) (18) (50)
Liver (50) (20) (50)
Hemangiosarcoma 1 (2%)
Hemangiosarcoma, Metastatic 1 (2%)
Hepatocellular Carcinoma 1 (2%) 1 (5%) 2 (4%)
Hepatocellular Adenoma 2 (4%) 1 (5%) 4 (8%)
Hepatocholangiocarcinoma 1 (5%)
Histiocytic Sarcoma 1 (2%)
Sarcoma 1 (5%)
Pancreas (50) (16) (50)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (6%)
Salivary Glands (49) (14) (49)
Stomach, Forestomach (50) (19) (49)
Squamous Cell Papilloma 1 (5%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (15) (50)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
Hemangiosarcoma, Metastatic, Spleen 1 (2%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (7%)
____________________________________________________________________________________________________________________________________
Page 2
NTP Experiment-Test: 05095-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC EPINEPHRINE HCL Date: 09/13/94
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 00:50:55
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 1.5MG/M3 3.0MG/M3
FEMALE FEMALE FEMALE
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Gland (50) (17) (50)
Capsule, Adenoma 1 (2%)
Adrenal Gland, Cortex (50) (16) (50)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (6%)
Pituitary Gland (49) (46) (49)
Adenoma 7 (14%) 11 (24%) 12 (24%)
Pars Intermedia, Adenoma 1 (2%)
Thyroid Gland (49) (18) (48)
Bilateral, Follicular Cell, Adenoma 1 (6%)
Follicular Cell, Adenocarcinoma 1 (2%)
Follicular Cell, Adenoma 3 (6%) 1 (6%) 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Ovary (50) (26) (50)
Adenocarcinoma 1 (4%)
Adenoma 1 (4%)
Cystadenoma 3 (6%) 1 (2%)
Hemangioma 1 (4%)
Teratoma 1 (2%)
Uterus (50) (19) (50)
Adenocarcinoma 1 (5%) 2 (4%)
Adenoma 1 (2%) 1 (5%)
Fibrous Histiocytoma 1 (2%)
Hemangiosarcoma 1 (2%)
Histiocytic Sarcoma 1 (2%)
Leiomyoma 1 (5%)
Sarcoma Stromal 1 (2%)
Endometrium, Polyp Stromal 1 (5%) 3 (6%)
Vagina (1)
Sarcoma Stromal, Metastatic, Uterus 1 (100%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (50) (15) (50)
Lymph Node (50) (29) (49)
Lymph Node, Bronchial (45) (20) (49)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
Page 3
NTP Experiment-Test: 05095-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC EPINEPHRINE HCL Date: 09/13/94
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 00:50:55
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 1.5MG/M3 3.0MG/M3
FEMALE FEMALE FEMALE
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - cont
Lymph Node, Mandibular (49) (19) (45)
Spleen (50) (25) (50)
Hemangioma 1 (2%)
Hemangiosarcoma 1 (2%)
Hemangiosarcoma, Metastatic, Skin 1 (4%)
Hemangiosarcoma, Metastatic, Skeletal Muscle 1 (2%)
Thymus (46) (14) (45)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (44) (14) (45)
Adenoacanthoma 1 (2%)
Adenocarcinoma 1 (2%) 2 (4%)
Skin (49) (23) (49)
Subcutaneous Tissue, Hemangiosarcoma 2 (9%)
Subcutaneous Tissue, Mast Cell Tumor
Malignant 1 (4%)
Vulva, Papilloma 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Skeletal Muscle (1)
Hemangiosarcoma 1 (100%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50) (15) (50)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Larynx (50) (14) (50)
Lung (50) (27) (50)
Alveolar/Bronchiolar Adenoma 3 (6%) 5 (19%)
Alveolar/Bronchiolar Adenoma, Multiple 1 (2%)
Alveolar/Bronchiolar Carcinoma 1 (2%) 1 (2%)
Alveolar/Bronchiolar Carcinoma, Multiple 1 (2%)
Hemangiosarcoma, Metastatic 1 (2%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (4%)
Histiocytic Sarcoma 1 (2%)
Osteosarcoma, Metastatic, Uncertain Primary
Site 1 (4%)
Sarcoma, Metastatic, Liver 1 (4%)
Nose (50) (48) (50)
Page 4
NTP Experiment-Test: 05095-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC EPINEPHRINE HCL Date: 09/13/94
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 00:50:55
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 1.5MG/M3 3.0MG/M3
FEMALE FEMALE FEMALE
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM - cont
Turbinate, Hemangioma 1 (2%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (2)
Adenocarcinoma 1 (50%)
Adenoma 1 (50%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (19) (50)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (5%)
Renal Tubule, Adenoma 1 (2%)
Urinary Bladder (50) (15) (50)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50) *(50)
Histiocytic Sarcoma 1 (2%)
Lymphoma Malignant Histiocytic 1 (2%)
Lymphoma Malignant Lymphocytic 1 (2%) 2 (4%) 7 (14%)
Lymphoma Malignant Mixed 15 (30%) 15 (30%) 7 (14%)
Lymphoma Malignant Undifferentiated Cell 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 5
NTP Experiment-Test: 05095-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC EPINEPHRINE HCL Date: 09/13/94
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 00:50:55
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 1.5MG/M3 3.0MG/M3
FEMALE FEMALE FEMALE
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 36 35 30
Total Primary Neoplasms 49 53 52
Total Animals with Benign Neoplasms 19 19 19
Total Benign Neoplasms 23 26 25
Total Animals with Malignant Neoplasms 25 26 23
Total Malignant Neoplasms 26 27 27
Total Animals with Metastatic Neoplasms 1 4 4
Total Metastatic Neoplasm 2 8 5
Total Animals with Malignant Neoplasms 1
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 6
NTP Experiment-Test: 05095-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC EPINEPHRINE HCL Date: 09/13/94
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 00:50:55
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 1.5MG/M3 3.0MG/M3
MALE MALE MALE
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 50 50 50
Early Deaths
Dead 10 4 4
Moribund 7 12 10
Survivors
Terminal Sacrifice 33 34 36
Animals Examined Microscopically 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Liver (50) (25) (50)
Hemangiosarcoma 1 (2%) 1 (4%) 1 (2%)
Hemangiosarcoma, Metastatic, Spleen 1 (2%) 1 (2%)
Hepatocellular Carcinoma 11 (22%) 7 (28%) 10 (20%)
Hepatocellular Carcinoma, Multiple 1 (2%)
Hepatocellular Adenoma 10 (20%) 5 (20%) 6 (12%)
Hepatocellular Adenoma, Multiple 2 (8%)
Histiocytic Sarcoma, Metastatic, Skin 1 (2%)
Stomach, Forestomach (47) (16) (50)
Mast Cell Tumor Malignant, Metastatic, Bone
Marrow 1 (2%)
Squamous Cell Papilloma 1 (6%)
Stomach, Glandular (49) (16) (50)
Sarcoma, Poorly Differentiated 1 (6%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (16) (50)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (6%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Gland, Cortex (50) (32) (48)
Adenoma 1 (2%)
Adrenal Gland, Medulla (48) (16) (45)
Pituitary Gland (50) (16) (48)
Thyroid Gland (49) (15) (50)
Follicular Cell, Adenoma 1 (2%)
____________________________________________________________________________________________________________________________________
Page 7
NTP Experiment-Test: 05095-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC EPINEPHRINE HCL Date: 09/13/94
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 00:50:55
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 1.5MG/M3 3.0MG/M3
MALE MALE MALE
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Prostate (48) (13) (49)
Testes (50) (15) (50)
Hemangioma 1 (2%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (50) (16) (50)
Hemangiosarcoma, Metastatic, Spleen 1 (2%) 1 (2%)
Calvarium, Mast Cell Tumor Malignant 1 (2%)
Lymph Node (49) (20) (50)
Lymph Node, Bronchial (43) (13) (49)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
Mediastinal, Alveolar/Bronchiolar Carcinoma,
Metastatic, Lung 1 (2%)
Lymph Node, Mandibular (43) (12) (41)
Mast Cell Tumor Malignant, Metastatic, Bone
Marrow 1 (2%)
Spleen (50) (20) (50)
Hemangiosarcoma 1 (2%) 1 (5%) 3 (6%)
Hemangiosarcoma, Metastatic, Skin 2 (4%)
Mast Cell Tumor Malignant, Metastatic, Bone
Marrow 1 (2%)
Thymus (41) (12) (33)
Osteosarcoma, Metastatic, Bone 1 (2%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (48) (21) (49)
Basal Cell Carcinoma 1 (5%)
Subcutaneous Tissue, Fibrosarcoma 1 (2%)
Subcutaneous Tissue, Hemangiosarcoma 2 (4%)
Subcutaneous Tissue, Histiocytic Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
Page 8
NTP Experiment-Test: 05095-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC EPINEPHRINE HCL Date: 09/13/94
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 00:50:55
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 1.5MG/M3 3.0MG/M3
MALE MALE MALE
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (50) (16) (50)
Osteosarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50) (16) (50)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50) (32) (50)
Alveolar/Bronchiolar Adenoma 10 (20%) 8 (25%) 8 (16%)
Alveolar/Bronchiolar Adenoma, Multiple 1 (2%) 1 (3%) 2 (4%)
Alveolar/Bronchiolar Carcinoma 5 (10%) 3 (9%) 5 (10%)
Alveolar/Bronchiolar Carcinoma, Multiple 1 (2%)
Carcinoma, Metastatic, Harderian Gland 1 (3%)
Hepatocellular Carcinoma, Multiple,
Metastatic, Liver 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 2 (4%) 2 (6%) 2 (4%)
Osteosarcoma, Metastatic, Bone 1 (2%)
Mediastinum, Hemangioma 1 (2%)
Nose (50) (50) (50)
Respiratory Epithelium, Papilloma 1 (2%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Ear (1)
Fibrosarcoma 1 (100%)
Eye (1)
Fibrosarcoma 1 (100%)
Harderian Gland (2) (2) (2)
Adenoma 2 (100%) 1 (50%) 2 (100%)
Carcinoma 1 (50%) 1 (50%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (16) (50)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (6%)
Urinary Bladder (50) (16) (50)
Page 9
NTP Experiment-Test: 05095-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC EPINEPHRINE HCL Date: 09/13/94
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 00:50:55
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 1.5MG/M3 3.0MG/M3
MALE MALE MALE
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50) *(50)
Histiocytic Sarcoma 1 (2%)
Lymphoma Malignant Lymphocytic 1 (2%) 2 (4%)
Lymphoma Malignant Mixed 7 (14%) 5 (10%) 3 (6%)
Lymphoma Malignant Undifferentiated Cell 1 (2%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 10
NTP Experiment-Test: 05095-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC EPINEPHRINE HCL Date: 09/13/94
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 00:50:55
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 1.5MG/M3 3.0MG/M3
MALE MALE MALE
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 38 33 33
Total Primary Neoplasms 56 41 49
Total Animals with Benign Neoplasms 20 17 19
Total Benign Neoplasms 24 18 22
Total Animals with Malignant Neoplasms 25 21 20
Total Malignant Neoplasms 32 23 27
Total Animals with Metastatic Neoplasms 8 4 7
Total Metastatic Neoplasm 10 5 9
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 11
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------
--multipart-boundary
Content-type: text/plain
Range: bytes 62456-62456/62456
--multipart-boundary--